Pharmaron Acquires Majority Ownership in LinkStart
Expands Pharmaron’s integrated offerings to clinical development in China
康龍化成宣布控股聯斯達
旨在進一步布局中國臨床開發一體化服務能力
Beijing, China, July 3rd, 2020 - Pharmaron, a fully integrated contract research and manufacturing organization offering end-to-end R&D services for the life science industry, announced today that it completed a follow-on investment to acquire the majority ownership in Beijing LinkStart SMO Ltd.(Linkstart), a third party clinical site management services organization (“SMO”) headquartered in Beijing, China. With the completion of this transaction, LinkStart becomes a subsidiary of Pharmaron.
中國，北京， 2020年7月3日
康龍化成宣布完成控股北京聯斯達醫藥科技發展有限公司（提供第三方獨立臨床研究現場管理服務SMO，總部位于北京，英文名：LinkStart SMO Ltd.，以下簡稱聯斯達）的交易，聯斯達成為康龍化成的子公司。
This investment follows the path of Pharmaron’s previous strategic investment made in LinkStart in 2019, reflecting its continued confidence in LinkStart and strong commitment to clinical development service. This transaction will facilitate the implementation of Pharmaron’s clinical service strategy in China and in the world.
作為2019年戰略性投資聯斯達之后的追加投資，此次交易體現了康龍化成對聯斯達的信心，彰顯公司對拓展臨床開發服務領域的決心，此舉將促進公司在中國及全球臨床服務能力建設。
Mr. Larry Lou, President and COO of Pharmaron commented, “We are delighted to have LinkStart join the Pharmaron family. Through this investment, together with our clinical CRO subsidiary CR Medicon, we will be able to further strengthen our clinical service capability and capacity in China. It is one step closer to realize Pharmaron’s strategy to integrate its global clinical platforms in China, the US and the UK, all together, creating additional, synergistic value for domestic and international partners. It will help create an end-to-end service platform ranging from discovery through preclinical to clinical development and manufacturing.”
康龍化成總裁兼COO樓小強先生表示：“歡迎聯斯達加入康龍化成大家庭！結合之前對南京希麥迪的收購，我們在中國的臨床開發服務能力得到進一步強化?？谍埢芍铝τ趹鹇孕詷嫿ㄅR床開發服務一體化平臺，整合中、英、美三地優勢，發揮協同效應，為國內外合作伙伴創造價值?！?/p>
Mr. Yang Liu, founder, CEO of LinkStart, expressed his enthusiasm about this transaction, “We are excited to join the Pharmaron group, a highly experienced global player in the life science service industry. With the strong support from Pharmaron since the strategic investment last year, the SMO service capability and business in LinkStart has grown rapidly. By further deepening our relationship, we are in a better position to serve our partners and to build a premier SMO brand in the life science industry.”
聯斯達創始人、CEO劉洋先生對此次交易表示期待：“康龍化成在國際生命科學研發服務領域備具豐富的經驗，我們很高興加入這樣的大家庭。聯斯達自去年接受康龍化成戰略投資后，獲得了康龍化成強有力的支持，公司在SMO業務能力和業務體量均快速增長。此次進一步強化彼此伙伴關系，有利于我們更全面地融入康龍化成新藥研究和開發服務大平臺，為客戶提供更優質的服務，打造行業領先的SMO品牌。我們對此充滿信心?！?nbsp;
About Pharmaron
Pharmaron (Stock Code: 300759.SZ/3759.HK) is a leading fully-integrated pharmaceutical R&D service platform supporting the life science industry. Founded in 2004, Pharmaron has invested in its people and facilities and established its comprehensive service offerings throughout the pharmaceutical R&D lifecycle. With operations in China, US and UK staffed by over 8,000 employees, Pharmaron has excellent track record in delivering R&D solutions to its partners in North America, Europe, Japan and China.
For more information: www.pharmaron.com
About LinkStart
LinkStart is a leading clinical SMO in China. Founded in 2012, headquartered in Beijing. LinkStart collaborates with over 500 hospitals in more than 110 cities in China, and is a preferred SMO service provider for100+ clinical research centers. LinkStart has conducted 900+ studies, of which 85% are the 1st class of new drugs and biological products, encompassing a broad spectrum of therapeutic areas.
